Biocept Looks toward China to Market Cancer Diagnosis Technology

Biocept, a San Diego device maker, plans to expand to China after being awarded a China patent for its blood-borne oncology diagnostic tests. The company positions its microfluidic channel technology as an alternative to a biopsy in patients who have been diagnosed with cancer. Biocept's technology identifies and enumerates circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the blood to help guide treatment and monitor changes in the tumor. More details.... Stock Symbol: (NSDQ: BIOC) Share this with colleagues: // //